Visit their website here https://www.genscript.com/
GenScript Biotech Corporation is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
Every day, scientists around the world are tackling chronic diseases and infections at the cellular level to understand causes, identify treatments and test new drugs and vaccines. Danaher’s Life Sciences companies make this leading-edge scientific research possible at clinical research facilities, academic institutions and government agencies. Our capabilities extend beyond research with the world’s most advanced filtration, separation and purification technologies, which power the creation of biopharmaceuticals, microelectronics and more.
Contributing to Society through Healthcare,” is both Terumo’s starting point and unchanging group mission since founded in 1921. Keeping Dr. Kitasato’s spirit of innovation and challenge alive, we strive to bring outstanding innovation to medicine and enable the best possible care for patients. Among our seven business areas, Alliance Division offers pharmaceutical companies advanced devices that utilize Terumo’s experience and expertise built through years of prefilled product manufacturing. We develop administration devices (including syringe and needle) made from materials tailored to each drug, and provides contract manufacturing that leverages Terumo’s advanced manufacturing technology for drug-device combination products. Through alliances with pharmaceutical companies, the Alliance Division provides a total solution, from clinical trial drug manufacture to full commercialization, contributing to safer and more certain delivery of the drugs patients need.
We are a focused industrial supplier with leading positions in global and regional market segments. With a total of more than 50 operating companies, sales in over 100 countries and some 7,500 employees, we generate annual revenue of some CHF 1,300 million.
The Datwyler Sealing Solutions Division is a leading supplier of customer specific sealing, closure and packaging solutions to global market segments, such as the Automotive, Health Care, Civil Engineering and Consumer Goods industries. This is thanks to its leading material, engineering and process expertise and worldwide presence with its own production locations. As an acknowledged development partner, Datwyler maintains close working relationships with global customers, and has in-depth knowledge of the business models and technologies used in the markets in which it operates.